3064 NEJ016: Phase II study of carboplatin and weekly paclitaxel plus bevacizumab followed by bevacizumab for highly selected elderly non-squamous non-small cell lung cancer patients
Teruichi Harada, H. Yoshizawa, Akihiko Gemma(Nippon Medical School), Takayuki Nakagawa(Shionogi (Japan)), Mitsuo Terada, Satoru Miura(Niigata Cancer Center Hospital), Keigo Kobayashi(Osaka Gakuin University), Takashi Ishida(Keio University), Masahiro Seike(Nippon Medical School Hospital), Akira Iwashima, A. Inoue, Hiroshi Watanabe(Tohoku University), Shunichi Sugawara(Sendai Kousei Hospital), Y Takiguchi, Makoto Maemondo(Miyagi Prefectural Hospital Organization)
Cited by 0
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695